David A. Siegel Veracyte, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Veracyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 15,300 shares of VCYT stock, worth $662,949. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,300
Previous 20,400
25.0%
Holding current value
$662,949
Previous $442,000
17.65%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding VCYT
# of Institutions
308Shares Held
81.8MCall Options Held
134KPut Options Held
13.3K-
Black Rock Inc. New York, NY7.79MShares$338 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.75MShares$336 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.02MShares$218 Million0.27% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.92MShares$213 Million1.59% of portfolio
-
Wellington Management Group LLP Boston, MA4.23MShares$183 Million0.03% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $3.1B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...